12/11
12:30 pm
trml
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.
12/11
12:30 pm
trml
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Guggenheim.
12/11
12:03 pm
trml
Rating for TRML
Low
Report
Rating for TRML
12/11
12:03 pm
trml
Rating for TRML
Low
Report
Rating for TRML
12/11
11:29 am
trml
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.
Low
Report
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.
12/11
11:22 am
trml
Rating for TRML
Low
Report
Rating for TRML
12/11
08:21 am
trml
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Medium
Report
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
12/6
08:13 am
trml
Tourmaline Bio, Inc. (NASDAQ: TRML) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $50.00 price target on the stock.
Low
Report
Tourmaline Bio, Inc. (NASDAQ: TRML) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $50.00 price target on the stock.
12/6
06:16 am
trml
Rating for TRML
Medium
Report
Rating for TRML
12/6
06:16 am
trml
Rating for TRML
Medium
Report
Rating for TRML
12/5
04:17 pm
trml
Tourmaline Bio initiated with an Outperform at BMO Capital
Low
Report
Tourmaline Bio initiated with an Outperform at BMO Capital
12/5
04:17 pm
trml
Tourmaline Bio initiated with an Outperform at BMO Capital
Low
Report
Tourmaline Bio initiated with an Outperform at BMO Capital
10/16
07:43 am
trml
Tourmaline Bio, Inc. (NASDAQ: TRML) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Tourmaline Bio, Inc. (NASDAQ: TRML) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
10/15
08:41 am
trml
Tourmaline Bio initiated with bullish view at Cantor Fitzgerald
Low
Report
Tourmaline Bio initiated with bullish view at Cantor Fitzgerald